Sionna Therapeutics
SION46.5502.58% ( +1.170 )
Sionna Therapeutics (SION)
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops...
- Open
- 45.410
- High
- 46.690
- Low
- 44.110
- Prev. Close
- 45.380
- Volume
- 320.21K
- Turnover
- 14.61M
- Avg Price
- 45.613
- Bid/Ask Ratio
- --
- Amplitude
- 5.69%
- 52wk High
- 51.565
- Volume Ratio
- 0.36
- Turnover Ratio
- 1.91%
Sionna Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 24, 2026Price forecast
$51.6010.85%
Forecast & RatingBuy
11analysts
- Strong buy72.73%
- Buy9.09%
- Hold9.09%
- Sell0.00%
- Strong sell9.09%
News
- Simplywall · Jul 21 at 12:13 AM
Sionna Therapeutics (SION) Pulls Back On CF Hopes With Valuation Still In Focus
- Tip Ranks · Jul 20 at 08:15 AM
Sionna Therapeutics, Inc. (SION) Receives a Rating Update from a Top Analyst
- rttnews · Jul 19 at 12:05 PM
5 Undervalued Stocks That Soared: SION +277%, FBRX +306%, NKTR +869% & More
- Market Beat · Jul 18 at 03:20 AM
Sionna Therapeutics (NASDAQ:SION) Hits New 12-Month High - Should You Buy?
- PUBT · Jul 9 at 03:44 PM
OrbiMed Advisors disposes of 85,918 Sionna Therapeutics shares worth $3.85 million
- PUBT · Jul 7 at 03:38 PM
Sionna Therapeutics Chief Legal Officer Jennifer Fitzpatrick disposes of 10,250 common shares worth $446,862.08
